Cabaletta Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cabaletta Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-66.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 77% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-5.4×Operating cash was negative last year, while some debt falls due within a year.
Higher than 58% of Healthcare companies in United States.
Cash Cushion Ratio
+41%Cash, after subtracting all debt, equals 41% of its market value (net cash).
Higher than 75% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Cabaletta Bio, Inc. made a loss over the last year. Cabaletta Bio, Inc. owes $0.18 for every $1 it owns. Cabaletta Bio, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCabaletta Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.22The share price is 1.22 times Cabaletta Bio, Inc.'s book value per share, lower than 75% of Healthcare companies in United States.
Market cap
$258 MThe total market value of all of Cabaletta Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$211 MWhat Cabaletta Bio, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.24Net worth divided by the number of shares. The share price of $1.52 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
-93.2%Cabaletta Bio, Inc. lost 93.2% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
Owes vs Owns
0.18×Cabaletta Bio, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Dividend yield
NoneCabaletta Bio, Inc. does not currently pay a dividend.
Profit growth
LossCabaletta Bio, Inc. made a loss in each of the last two years.
Interest cover
Not coveredCabaletta Bio, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCabaletta Bio, Inc. held $107 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cabaletta Bio, Inc.: $258 M ÷ $211 M (30 Jun 2026) = 1.2.
What is Cabaletta Bio, Inc.'s return on equity?
Cabaletta Bio, Inc. lost 93.2% of its shareholders' money over the last year, lower than 69% of Healthcare companies in United States.
How much does Cabaletta Bio, Inc. owe compared with what it owns?
Cabaletta Bio, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Does Cabaletta Bio, Inc. pay a dividend?
No. Cabaletta Bio, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.